Innovative new international trial for relapsed paediatric ALL opens soon
A clinical trial, due to open in mid-2022, will give young people access to two promising new ALL drugs.
- Acute lymphoblastic leukaemia
- Clinical trials
- Research
Category: Research
Expert Series: Professor John Seymour
Find out why the clinical haematologist is dedicating his life to CLL.
- Chronic lymphocytic leukaemia
- Interviews with experts
Support for submission to MSAC for MRD testing reimbursement in ALL
- Acute lymphoblastic leukaemia
- Treatments and side-effects
MSAC advising on cilta-cel CAR T-cell therapy for myeloma
Ciltacabtagene autoleucel (cilta-cel), is being appraised by the Medical Services Advisory Committee (MSAC) for listing on the Medicare Benefits Schedule.
- Myeloma
Venetoclax moves us closer towards zero lives lost to blood cancer
- Advocacy and policy
- Research
Expert Series: Professor Andrew Perkins on MPN
It’s emerging in all cancers, but particularly in the MPNs, that “genomics is everything” according to Professor Andrew Perkins, an expert in myeloproliferative neoplasms (MPN).
- Interviews with experts
- Myeloproliferative neoplasms
- Research
New international trial for amyloidosis
In a first-ever Australian-French collaboration, an exciting new clinical trial, due to open before Christmas, will give Australians with relapsed or refractory AL amyloidosis access to a new drug combination.
- Amyloidosis
- Clinical trials
- Research
- Treatments and side-effects
Expert Series: Dr Ilaria Pagani talks treatment-free remission in CML
Dr Pagani has a vision for a personalised approach to treatment-free remission in CML
- Chronic myeloid leukaemia
- Interviews with experts
- Research
Revised AML, DLBCL and HL Optimal Care Pathways released
Newly revised optimal care pathways (OCPs) provide best practice information for the treatment and care of people living with acute myeloid leukaemia (AML), and diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL).
- Acute myeloid leukaemia
- Chronic myeloid leukaemia
- Hodgkin lymphoma
Expert Series: Dr Chun Fong on finding the keys to unlock AML
Dr Chun Fong believes that testing for minimal residual disease (MRD) is part of the answer.
- Acute myeloid leukaemia
- Interviews with experts
- Research
- “Live life to the fullest”: Josh Gourlay opens up about returning to work and new beginnings after blood cancer
- Advocacy news – July 2024
- Talking Blood Cancer: Estate planning and medical directives
- Running for a Cause: Cal Gates’ Journey from Newcastle to Sydney on foot in one weekend
- World Blood Cancer Day 2024